STAT+: Trump’s Drug-Pricing Deals Set to Be Tested by New Product Launches

Why It Matters

The first transparent pricing data will show whether MFN deals can curb U.S. drug costs, influencing future regulatory approaches and industry pricing strategies.

Key Takeaways

• Trump’s MFN deals cover 17 pharma companies
• New drugs must match net prices in peer wealthy nations
• Baxfendy, Awiqli, and Veppanu will be first price‑transparent launches
• Veppanu lacks foreign reference, testing MFN pricing limits
• Industry watches for pricing impact on U.S. drug costs

Pulse Analysis

The Trump administration’s most‑favored‑nation (MFN) drug‑pricing policy was introduced as a bipartisan effort to curb soaring prescription costs. By tying U.S. net prices to those in a basket of affluent countries, the White House estimates the approach could generate roughly $5.3 billion in savings over the next decade. While the exact mechanics remain confidential, the policy obliges participating manufacturers—currently 17 major firms—to adopt reference pricing for any new product launched in the United States, a move that could reshape pricing negotiations across the sector.

The first real‑world test arrives with three upcoming launches. AstraZeneca’s Baxfendy, a novel hypertension therapy, Novo Nordisk’s Awiqli insulin, and the oncology candidate Veppanu—co‑developed by Arvinas and Pfizer and slated for licensing to Rigel—will be the inaugural drugs whose U.S. net prices are publicly disclosed under the MFN framework. Baxfendy and Veppanu are not yet marketed in the reference nations, forcing companies to estimate comparable foreign prices, while Awiqli already has established benchmarks. This mix of known and unknown reference points will illuminate how strictly manufacturers can adhere to MFN pricing without sacrificing market entry strategies.

Stakeholders are watching closely. Transparent pricing could pressure pharma firms to lower U.S. list prices, potentially narrowing the gap with international markets and delivering tangible savings for insurers and patients. Conversely, companies may adjust launch timing or seek exemptions, testing the policy’s elasticity. The outcomes will inform future legislative tweaks, guide payer negotiations, and signal whether reference‑based pricing can become a durable tool in the U.S. drug‑cost containment arsenal.